Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2012

View Archived Issues

Research at Allergan yields novel lysophospholipid receptor ligands

ARRY-614 active in phase I trial

Janssen-Cilag withdraws application to extend approval of Velcade

Chelsea Therapeutics receives feedback on resubmitted Northera NDA

Buparlisib administered with trametinib dimethyl sulfoxide in cancer study

Phase I results available for OPB-51602

Team at Roche patents new PDE10A inhibitors

Bristol-Myers Squibb prepares new HIV attachment inhibitors

New KIF11 inhibitors discovered in Japan

U.S. university presents novel inhibitors of PRCP

Novel compounds for bone disorders designed in Japan

Novel bromodomain-containing protein inhibitors synthesized

Salivary interleukins as possible markers of periodontal tissue destruction

Second patient undergoes subretinal transplant in phase I/II trial

NP-2 enkephalin study does not meet primary objective

Apeptico kicks off phase II AP-301 study

FDA approves first over-the-counter HIV test

Enrollment complete in phase IIb trial of tozadenant

Global pediatric studies of long-lasting hemophilia A and B product candidates begin

Recruitment complete in pivotal Ruconest study

Maximum tolerated dose of NKP-1339 determined in first-in-human trial

SB-485232/PLD combination shows acceptable safety in ovarian cancer

Macrocyclic inhibitors for Flaviviridae infections presented

EXPAND trial in advanced gastric cancer does not meet primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...